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Background: Clinical gene therapy trials for cardiovascular diseases have demonstrated the crucial role of efficient
gene delivery and transfection technologies in achieving clinically relevant results. We hypothesized that the use of
tropism-modified adenoviruses would improve transduction efficacy and to this end we analyzed the transduction
efficiency and toxicity of standard Ad5 and tropism-modified Ad5/35 in combination with ultrasound-guided
intramyocardial gene delivery.
Methods: Ultrasound-guided intracardiac injections were used to deliver 1 × 1010 pfu/ml Ad5-lacZ and Ad5/35-lacZ
vectors into mouse left ventricle wall. Since Ad5/35 uses human CD46 as its primary receptor, we used transgenic
hCD46Ge mice expressing human CD46 at levels comparable to man. Mice were sacrificed 6 or 14 days
post-injection and immunohistochemistry and X-gal staining were used to detect transgene and viral receptor
expression. Virus-induced cardiac toxicity was evaluated by a pathologist.
Results: The intramyocardial injection was well tolerated and both Ad5-lacZ and Ad5/35-lacZ were able to give
robust transgene expression after a single injection. Interestingly, while Ad5-lacZ was able to generate greater
transgene expression than Ad5/35-lacZ, it also evoked more severe tissue damage with large areas of interstitial
inflammatory cell infiltration and myocyte necrosis.
Conclusions: Ultrasound-guided intramyocardial injection is an effective and safe way to deliver vectors to the
heart. The observed severe tissue damage of Ad5-lacZ greatly undermines the efficient transgene expression and
suggests that Ad5/35 capsid modification can result in safer adenoviral vectors for cardiovascular gene therapy,
although at the cost of some vector transduction efficacy.
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Cardiovascular disease (CVD) is the leading causes of
death in the western world, even after steady decline due
to improved risk control and effective invasive treatment
methods. Annually over 190 000 people die from CVD
in the UK alone and the health care costs are over 3.2
billion pounds. As existing methods are clearly inadequate,* Correspondence: mikko.savontaus@btk.fi
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reproduction in any medium, provided the ornovel treatment methods, such as gene therapy, are clearly
needed.
Adenoviruses (Ads) are the most utilized gene therapy
vectors. Over 50 different Ad serotypes, divided in six
different subgroups (A-F) have been identified to date
[1]. Viruses in different subgroups have varying tissue
tropism and recognize different cellular receptors.
Coxsackie-adenovirus receptor (CAR) has been identi-
fied as the primary attachment receptor for many Ads,
including the most utilized serotype 5 (Ad5) [2-4].
Group B Ads have been shown to infect cells in CAR-
independent manner and the cellular receptor has been
identified as CD46 for most group B viruses [1,5,6].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ly expressed by all nucleated cells in human body [7].
Recently it was also reported that a subgroup of B
adenoviruses use desmoglein 2 receptor for primary
attachment [8], but serotype 35 was not included in
this group.
Several preclinical gene therapy strategies have been
used for cardiovascular disease using different viral vec-
tors and non-viral gene transfer and various modes of
administration [9]. Most clinical cardiovascular gene
therapy trials have used the standard Ad5 vector and
one of the lessons from these trials has been the key role
of efficient gene transfection and delivery in achieving
clinically meaningful therapeutic efficacy.Thus, it has
been clear that Ad vectors must be engineered to en-
hance their ability to transfect the target tissue. Several
methods have been developed to transductionally target
Ad vectors including the use of bivalent targeting com-
plexes and engineering genetic alterations to viral capsid
proteins [10]. One targeting method which has recently
been successfully used in many applications is to use hy-
brid adenoviruses, which are created by interchanging
capsid fibers between serotypes, usually with Ad5 receiv-
ing the fiber from another serotype [11]. In this study
we used such a hybrid vector, Ad5/35, which has fibers
from Group B Ad serotype 35 and thus uses CD46
instead of CAR to gain entry into cells. Previous data
demonstrate that Ad5/35 hybrid virus is able to effi-
ciently transduce many cell types that are relatively re-
sistant to Ad5 infection, including hematopoietic stem
cells, tumor endothelial cells, and several cancer
cell types [12-18]. Previously we have reported an ana-
lysis of various Ad receptors in both human dilated
cardiomyopathy (DCM) hearts and non-DCM hearts
demonstrating significant differences in expression
patterns of CAR and CD46, with CAR receptor dem-
onstrating higher expression in both DCM and non-
DCM hearts [19].
In addition to vector development, the method of
gene delivery plays a crucial role in achieving efficient
gene transfer to the heart. Various modes of adminis-
tration have previously been used to deliver genes to
the heart, including intravascular, intracoronary, intra-
myocardial and intramuscular routes. Ultrasound-
guided intramyocardial injection of gene delivery vec-
tors is an attractive and clinically applicable concept
to directly infect cardiomyocytes. In this study we
employed this method to test the hypothesis that
the use of tropism-modified adenoviruses would im-
prove transduction efficacy for cardiovascular applica-
tions and to this end evaluated the transductional
capability and toxicity of a capsid-modified Ad5/35
adenoviral vector in comparison to standard Ad5 vec-
tor in the heart.Materials and methods
Human CD46 transgenic mice
The transgenic mouse strain hCD46Ge was a generous
gift from Dr. Ann-Beth Jonsson, Uppsala University,
Sweden. These mice were constructed by using yeast
artificial chromosome technique as described earlier
[20]. In our studies the homozygous strain was used.
The CD46 receptor expression in hCD46Ge mice has
been analyzed earlier and it has been shown to be ubi-
quitously expressed, with the heart expressing all four
CD46 transcript variants [21]. All animal work was done
by trained scientists with permission from the Finnish
Laboratory Animal Board (license number: ESAVI-2010-
05655/Ym-23).Human heart samples
Human heart samples were used for immunohistochem-
istry of adenoviral receptor expression. Samples were a
kind gift from professor Petri Kovanen, Wihuri Institute,
Helsinki, Finland. Heart samples were obtained from left
ventricles of organ donors with no history of heart dis-
ease and whose donated heart could not be used for
transplantation. Immediately after collection the tissue
was frozen in liquid nitrogen and stored at -70°C. The
use of human heart samples as control specimens was
approved by the Institutional ethics committee of the
Helsinki University Central Hospital, and the investiga-
tion conforms to the principles outlined in the Declar-
ation of Helsinki.Adenoviral vectors
In this study we used two replication deficient adeno-
viral vectors, Ad5-lacZ and Ad5/35-lacZ. Both vectors
harbor Escherichia coli β-galactosidase gene under the
control of rous sarcoma virus (RSV) promoter. The
viruses were prepared by cotransfecting 293 cells with
shuttle plasmid pAd.RSV.LacZ and backbone plasmids
pBHG10 (for Ad5.LacZ), or pAdΔΨF35 (for Ad5/35.
LacZ) as previously described [22]. pAdΔΨF35 is based
on pBHG10 (MicrobixBiosystems Inc., Toronto, Canada)
and contains the chimeric Ad5/35 fiber gene instead of
Ad5 fiber gene [23]. Viruses were isolated from a single
plaque, expanded in 293 cells and purified by double
cesium gradient ultracentrifugation. Viral particles (vp)
were measured using standard absorbance method and
resulted in vp concentrations of 1.9 × 1012 for Ad5-lacZ
and 3.4 × 1012 for Ad5/35-lacZ. The plaque-forming
units (pfu) were determined by standard agarose-overlay
plaque assay on 293 cells resulting in pfu concentrations
9.3 × 1010 pfu/ml for Ad5-lacZ and 2.5 × 1010 pfu/ml for
Ad5/35-lacZ. The vp/pfu ratios were 20 for Ad5-lacZ
and 136 for Ad5/35-lacZ. For the in vivo experiments
both viruses were diluted to 1 × 1010 pfu/ml, indicating
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more viral particles than Ad5-lacZ mice.
Intracardiac injections
All animals received ultrasound-guided injection of
Ad5-lacZ (n = 8), Ad5/35-lacZ (n = 9), or PBS (n = 4)
into myocardium as previously described [24]. Briefly,
the procedure was accomplished under 2.5-3.5% isoflur-
ane anesthesia with the use of a Vevo770 (VisualSonics,
Toronto, Canada) equipped with a 30-MHz transducer.
After obtaining an optimal parasternal long-axis view,
the intramyocardial injection was performed via 30-
gauge needle by using micromanipulator. A volume of
10 μl (1 × 1010 pfu/ml) was injected in each heart deli-
vering 1 × 108 infectious particles of either Ad5-lacZ or
Ad5/35-lacZ vectors. During the procedure, mice
were immobilized to a warm plate, anesthetized with
isoflurane and their heart rate, respiration and body
temperature were monitored. No mice died from the
procedure and all were sacrificed 6 or 14 days post injec-
tion. The intramyocardial injection technique was also
validated using methylene blue dye injection to visualize
its distribution at myocardial sections after successful
injection (Additional file 1: Figure S1).
Serum samples
Blood was collected from the submandibular vein at
time points 6, 48 and 72 h post injection, into Capiject
T-MG serum collection tubes (Terumo, USA). Blood
was allowed to clot at least 20 min, before centrifuga-
tion. Serum was collected by pipetting, snap frozen in li-
quid nitrogen, and stored at -20°C before use. Cytokines
IL-6 and TNF-α were analyzed with custom Milliplex
assay kit (Millipore, USA) according to manufacturer’s
instructions.
Histology, Immunohistochemistry and Image Analysis
Each group of treated animals was divided into two end-
point groups 6 days and 14 days post injection. Mice
were sacrificed using CO2. Heart, lungs, and liver were
collected. Both frozen (for X-gal staining of reporter
gene analysis) and paraffin embedded (for histological
and toxicity analyses) sections were prepared from the
injected mouse hearts. In order to limit the number of
animals needed in the experiment, frozen sections for
reporter gene analysis were performed only from ani-
mals sacrificed at 6 days, whereas paraffin embedded
sections for histological and toxicity analyses were
performed from animals sacrificed at 6 and 14 days
post injection. Sections were stained with standard
Hematoxylin / Eosin staining.
Five micrometer sections were stained with Vectastain
HRP-kit (Vector laboratories, USA). The sections were
fixed onto Superfrost plus slides (O. Kindler GmbH,Germany) (frozen sections with cold acetone). The en-
dogenous peroxidase in frozen sections was inactivated
with 0.3% H2O2. Anti-CD46 primary antibody
(HPA016903, Sigma, USA) was used in 2 μg/ml dilution.
To evaluate signal from nonspecific antibody binding
normal Rabbit IgG sc-2027 (Santa Cruz, USA) was used
in 4 μg/ml dilution. Vectastain ABC-reagent was applied
on the sections (Vector Laboratories, USA), and recep-
tors were stained with diaminobenzidine (DAB, Sigma-
Aldrich, USA) and counterstained with Mayer’s
hematoxylin (Sigma-Aldrich, USA). Adenovirus induced
lacZ expression was visualized with X-gal staining in
frozen sections fixed with cold acetone and stained
with 0.2% X-gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside) solution according to supplier’s
instructions (Promega, Madison, WI) or by immunostain-
ing with anti-β-galactosidase antibody in paraffin embed-
ded sections.
The stained sections were photographed using a
microscope and evaluated for tissue damage by patholo-
gist, who was blinded to the experimental setting. We
used a grading system which gave 0-2 points for myo-
cyte damage, 0-2 points for interstitial inflammation and
0-1 points for endocardial involvement resulting in a
maximum possible score of 5. The inflammatory re-
sponse was quantified by calculating inflammatory area
using ImageJ software (National Institutes of Health,
Maryland, USA). To evaluate the spread of adenovirus-
mediated transgene expression, the X-gal stained specific
areas were measured by counting stained cells using
ImageJ software.
Tissue DNA extraction and PCR
10 mg of tissue was sectioned from frozen lung and liver
of Ad5-lacZ and Ad5/35-lacZ injected mice. DNA was
extracted with standard techniques: Tissue was first sub-
jected to proteinase K (400μg/ml) treatment, +50°C o/n.
Supernatant was collected after centrifugation 12 000 rpm,
5 min. DNA was extracted from the supernatant twice by
phenol:chloroform (1:1) extraction and purified with etha-
nol precipitation.
Purified DNA was used as a template in standard
qualitative PCR with Ad specific primers (forward:
CCATTTTCGCGGGAAAACTGA and reverse: AAGC
GCCATTCGCCATTC) amplifying RSV promoter area
and beginning of β-galactosidase gene carried by both
Ad5-lacZ and Ad5/35-lacZ vectors. DNA purified from
Ad5-lacZ vector stock was used as positive control.
Statistical analysis
The results are expressed as mean ± SD or median
[interquartile range]. The Shapiro-Wilk procedure was
applied to determine whether data are normally distribu-
ted. Independent sample t-test or Mann-Whitney U- test
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Changes in cytokine profiles were evaluated using one-
way ANOVA. Statistical analysis was performed using
SPSS 16 (SSPP Inc, Chicago, IL, USA). P-value less than
0.05 was considered significant.
Results
Animal model
As CD46 in mice is different from man and Ad35 uses
human CD46 to gain entry into cells, we used transgenic
hCD46ge mice, where human CD46 is expressed from a
yeast artificial chromosome and has similar CD46 ex-
pression pattern as humans. In order to establish the
validity of this model we confirmed the receptor expres-
sion by immunostaining with anti-huCD46 antibody.
Human CD46 expression was found throughout the
mouse cardiac tissue at comparable levels to human car-
diac tissue, indicating that CD46 expression is compar-
able in hCD46ge mice and humans (Figure 1).
Adenoviral transgene expression after intramyocardial
injection
We sought to compare transduction efficiencies between
equal amounts of Ad5-lacZ and Ad5/35-lacZ after
closed-chest echocardiography guided injection into the
free wall of the left ventricle. Echo images show clear li-
quid cloud during the injection, this cloud is alsoFigure 1 CD46 expression in the heart. A-B show heart tissue of hCD4
show positive anti-human CD46 receptor immunostaining on cell surfaces.
signal. The scale bar represents 100 μm.retained in the heart muscle after successful injection
(Figure 2), whereas injection into the ventricle cavity is
known to result in rapid clearance of “bubbles” into cir-
culation. We first validated this method by injecting
methylene blue to visualize the injected area. The dye
was repeatedly retained in the myocardium after suc-
cessful injection (Additional file 1: Figure S1).
No mice died from the procedure and no abnormal
behavior of animals was observed during the experi-
ment. Expression analyses were performed at 6 days post
injection and they revealed that both Ad5-lacZ and Ad5/
35-lacZ viruses were able to give robust transgene ex-
pression after a single injection of 1 × 108 pfu of virus
(Figure 3). The area of transduced cells after Ad5-lacZ
injection comprised approximately 13% of the total left
ventricle area (Figure 3A).When comparing the trans-
duced areas after Ad5-lacZ and Ad5/35-lacZ injection
we observed that Ad5-lacZ was able to transduce 2.99
times more cells as compared to Ad5/35-lacZ(p = 0.016)
(Figure 4A). The infected area with Ad5-lacZ was also
larger than with Ad5/35-lacZ.
Toxicity after adenoviral injection
In order to examine toxicity related to the virus injec-
tion, the heart and other organs were examined for
virus-related toxicity at 6 and 14 days post injection. In
the heart there was a clear difference between toxicities6ge transgenic mice and C-D human heart tissue. Panels A and C
Panels B and D are isotype controls showing the level of background
Figure 2 Successful ultrasound guided injection of left ventricle wall. A) Needle (white arrows) was inserted in between the ribs into the left
ventricle wall (outlined in blue) of anesthetized mouse. The needle tip (green arrow) was positioned intramyocardially without puncturing the left
ventricle lumen. B) A liquid cloud (red circle) becomes visible and is retained in the ventricle wall after successful injection.
Toivonen et al. Virology Journal 2012, 9:296 Page 5 of 9
http://www.virologyj.com/content/9/1/296elicited by the two viruses. At day 6 post injection both
vectors resulted in mild inflammatory reaction. At day
14 Ad5-lacZ was found to be significantly more toxic
than Ad5/35-lacZ. Ad5-lacZ vectors induced tissue dam-
age of over 11 times larger area than Ad5/35-lacZ vec-
tors as measured by infiltration of immune cells
(Figure 4B). The difference in the size of the affected
areas was statistically significant (p = 0.04). Ad5-lacZ
showed diffuse and severe inflammatory infiltrate,
mainly represented by lymphocytes. In addition myocyte
damage and necrosis were clearly seen as well as inter-
stitial fibrosis (Figures 3B and 3C). In comparison Ad5/Figure 3 Transgene expression and inflammatory response after intra
transgene expression and tissue damage after injection of Ad5-lacZ injectio
magnification image of B shows strong interstitial inflammatory cell infiltration
image of E, reveals weaker inflammation response and absence of myocyte d
(H and I). The sections were HE-stained and panels A, D and G show a light m
visualize transgene expression. The scale bar in panel F represents 200 μm (fo35-lacZ showed clearly less intense inflammatory infil-
trate and no myocyte necrosis (Figures 3E and 3F). At
14 days post injection Ad5/35-lacZ transduced heart
sections also showed features of resolving infection with
evident interstitial fibrosis. The inflammatory reaction
was also quantified by a pathologist with points given
for myocyte damage, interstitial inflammation and endo-
cardial involvement with a maximum possible score of 5
(Figure 4C). At 14 days post injection there was a signifi-
cant difference between the groups with inflammatory
grade score 3.4 for Ad5-lacZ and 1.0 for Ad5/35-lacZ
(p=0.009). Analysis of viral particle/pfu ratios indicatedmural injection of Ad5 and Ad5/35 vectors. Panels represent
n (A-C), Ad5/35-lacZ injection (D-F) or PBS (G-I). In panel C, a higher
, interstitial fibrosis and myocyte necrosis. Panel F, a higher magnification
amage. A mild needle tract reaction is seen in PBS-injected hearts
icroscopic view from the same myocardial region stained with X-gal to
r A-B, D-E and G-H) and 25 μm (for C, F and I).
Figure 4 Quantification of the transgene expression and inflammatory response after intracardiac injection. ImageJ software was used to
A) of X-gal positive infected cells at day 6 post injection B) the size of inflammatory response represented here as area A) expression after Ad5-lacZ
and Ad5/35-lacZ injection. Ad5-lacZ was able transduce significantly more cells than Ad5/35-lacZ (p = 0.016). B) Inflammatory response after Ad5-lacZ
and Ad5/35-lacZ injection. Both vectors resulted in mild inflammatory reaction at day 6 post injection. At day 14 Ad5-lacZ was found to be significantly
more toxic than Ad5/35-lacZ (p = 0.04). C) Grading of the inflammatory response. A pathologist analyzed inflammatory reaction using a grading
system for myocyte damage, interstitial inflammation and endocardial involvement. At 14 days the grading score was significantly higher for Ad5
(p=0.009). P-values ** p < 0.01, * p < 0.05.
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particles than Ad5-lacZ mice.
In order to analyze systemic toxicity, blood serum IL-
6 and TNF-α levels were analyzed at 6, 48 and 72
hours post injection (Figure 5). No significant elevation
or differences between Ad5 and Ad5/35 were observed
for either cytokine. Intramyocardial injection of both
viruses raised IL-6 levels within six hours postinjection, but after 3 days this elevation was observed
to be again close to pre injection levels. TNF-α levels
did not show similar transient change. We also evalu-
ated the presence of Ad DNA in the lung, liver and
spleen six days post injection by qualitative PCR. No
adenoviral DNA was detected in any of the tested tis-
sues of either Ad5-lacZ or Ad5/35-lacZ treated mice
(data not shown).
Figure 5 Analysis of serum cytokine levels from 0 to 3 days post injection. No statistically significant elevation of serum cytokine levels
were observed for A) IL-6 or B) TNF-α. Although both viruses raised IL-6 levels within six hours post injection, after 3 days this elevation was
observed to be again close to normal level. TNF-α levels did not show similar transient change.
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Despite the availability of several promising genes to
treat cardiovascular disease, their optimal delivery to the
heart remains a challenge. A number of gene delivery
vectors and methods of administration have previously
been used for cardiovascular applications with variable
success [9]. In this paper we combined two promising
approaches, hybrid adenoviral vectors and ultrasound-
guided intracardiac delivery, and analyzed the differences
in transduction efficiency and toxicity after intracardiac
injection between Ad5 and Ad5/35 vectors. We used a
transgenic mouse strain hCD46Ge, which expresses the
Ad5/35 receptor, human CD46, in a similar pattern as in
humans, to compare the viruses in a situation compar-
able to man [21,25].
The viral vectors were injected to the left ventricle wall
by using a closed-chest ultrasound guided system. With
this system vectors can be administered directly into the
left ventricle wall, without traumatic open-chest surgery.
The injection leaves only a minor needle track and no
other effects to cardiac function were observed. Safety of
this injection method has been shown in healthy C57BL
mice by advancing the needle 1-5 times to myocardium
and also by repeated saline injections without com-
promising left ventricular function (unpublished data,
Koskenvuo).
Transductional targeting has been widely used to im-
prove efficacy and reduce toxicity in various gene ther-
apy applications, most notably in cancer gene therapy
[26]. Numerous reports have demonstrated marked
improvements in therapeutic efficacy with the use of the
hybrid adenovirus technology. For cardiovascular gene
therapy, however, reports on transductional targeting
applications for the myocardium have thus far been
limited. We analyze here for the first time the effect
of adenoviral transductional targeting on transgeneexpression and toxicity after intramyocardial closed-
chest injection. Most previous studies involving adeno-
viral activity in the heart are biodistribution studies after
intravenous (i.v.) administration. It has been shown pre-
viously that after systemic i.v. administration both Ad5-
lacZ and Ad5/35-lacZ genomes are present at relatively
high concentrations in the hearts of hCD46Ge mice as
well as baboons and for Ad5/35-lacZ heart is one of the
most effectively transduced tissues in both models
[27,28]. Interestingly, with the primate model no trans-
gene activity was reported in the heart tissue for any
vector despite the presence of viral genomes. Analysis of
genome copies present in tissues does not discriminate
between active or inactive viral particles or between
intracellular genomes and viruses in extracellular space.
Unfortunately, only this method of analysis was
employed by Ganesh et al. (2009). Here we show also
the expression and activity of viral transgene in
hCD46Ge mice, indicating that transgenes from both
vectors are transcribed in our murine model. In their
work Ganesh et al. (2009) also analyzed vector-mediated
toxicity by measuring serum IL-6 and liver enzyme levels
and showed decreased overall toxicity with Ad5/35-lacZ
as compared to Ad5 vector after i.v. administration. The
highest serum IL-6 levels in our experiment were 87 pg/
ml, only 9% of the reported serum IL-6 levels after i.v.
administration (Figure 4) [27]. In addition, our analysis
of organs other than the heart revealed no signs of tox-
icity nor adenoviral DNA, indicating that systemic tox-
icity is low in our intracardiac injection model. Other
vector systems have previously been used for gene trans-
fer into the heart, including adeno-associated virus
(AAV). Previous studies have demonstrated high tropism
for the myocardium for AAV serotypes 1,6,8 and 9, mak-
ing the AAV system a potentially attractive delivery ve-
hicle for cardiovascular gene therapy [29]. The
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payload capacity and long experience from clinical
trials, and serotype-modification strategies can poten-
tially alleviate the strong immune response associated
with adenovirus treatment.
There are also a few previous reports using
ultrasound-guided intramyocardial injection of adeno-
virus in mice. Huusko et al. (2010) recently used this
method to inject Ad5 expressing lacZ or different iso-
forms of VEGF, and the inflammatory reaction was
found to be moderate at 14 days post injection, and the
level of tissue damage was found to be also dependent
on the transgene with VEGF-A giving rise to more in-
flammatory reaction than lacZ [30]. Li et al. (2005) used
an Ad5 vector with deletions of the E1, E2a, and E3
regions expressing inducible nitric oxide synthase and
reported little inflammatory reaction after intramyocar-
dial delivery [31].
Our previous studies on adenoviral receptor expres-
sion in human heart tissue suggested that the native Ad5
capsid configuration would be better suited for cardiac
gene transfer than Ad5/35 vectors as CAR had higher
levels of expression than CD46 in both normal
and dilated cardiomyopathy hearts [19]. As expected,
the injection of unmodified Ad5 vector resulted
in significantly more efficient transgene expression
than administration of hybrid vector Ad5/35 (Figure 3,
Figure 4). However, although both vectors elicited an im-
mune response, this response was markedly more severe
after Ad5 administration. At 6 days post injection there
was not a significant difference in toxicities between the
two viruses but by 14 days the Ad5 immune reaction
showed signs of irreversible tissue damage with large
areas of myocyte necrosis, whereas Ad5/35 had features
of resolving immune reaction. These results are in ac-
cordance with a previous report from Nanda et al.,
where the addition of Ad5 fiber knob to Ad35-based
vectors was found to substantially increase the immuno-
genicity of Ad vectors [32]. LacZ transgene is also im-
munogenic and it is theoretically possible that the
increased toxicity of Ad5 observed here could be caused
by higher expression of lacZ. However, previous studies
using different AAV vectors to deliver lacZ to mouse
hearts have shown a mild immune response and no
overt abnormalities in cardiac function despite high
levels of lacZ expression, suggesting that immune re-
sponse to lacZ does not play a significant role in our
model [33].
The results suggest that, although Ad5 is more effect-
ive in transducing cardiac cells after intracardiac injec-
tion, this vector clearly has a worse safety profile and
safer gene delivery can be achieved by using Ad5/35 hy-
brid vector. The definitive tissue damage after Ad5 injec-
tion will undermine the therapeutic effect of thedelivered transgene and probably lead to severe side
effects, although no adverse effects were evident during
the 14 day post injection observation period. It must be
also noted that even though Ad5 injection resulted in
more efficient transgene expression, the cardiac tissue
was not refractory to Ad5/35 infection and robust trans-
gene expression was also achieved using this vector. It is
notable that due to differences in viral particle/pfu ratios
between the two viruses, Ad5/35-lacZ mice received
6.65 times more viral particles and still demonstrated
less toxicity than A5-lacZ mice.
Results described here together with previous studies
suggest that changing Ad5 fiber to those of Ad35
increases the safety profile of gene therapy vectors, al-
though at the cost of some transduction efficiency.
Ultrasound-guided intracardiac injection is a promising
method for introducing genes to the heart. The
increased safety with Ad5/35 vector warrants for further
development of hybrid vector system for therapeutic
purposes.
Additional file
Additional file 1: Figure S1. Validation of ultrasound-guided
intramyocardial injection technique for therapeutic purposes using
methylene blue as an indicator for successful procedure. Left ventricle is
cut to five short-axis sections from basis to apex (left to right in Figure).
Dye injection produces darker outlook in the anterior myocardium of the
three midventricular slices.
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